Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim-Reference-Cited by-同舟云学术

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

Published:2011-03 Issue:3 Volume:77 Page:184-197
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Gascón Pere,Aapro Matti,Ludwig Heinz,Rosencher Nadia,Turner Matthew,Song MinKyoung,MacDonald Karen,Lee Christopher,Muenzberg Michael,Abraham Ivo

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference30 articles.

1. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia;Lalami;Supportive Care in Cancer,2004

2. Risk models for predicting chemotherapy-induced neutropenia;Lyman;The Oncologist,2005

3. Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review;Kuderer;Journal of Clinical Oncology,2007

4. The impact of chemotherapy delays on quality of life in patients with cancer;Calhoun;Journal of Supportive Oncology,2004

5. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics;Wingard;Critical Reviews in Oncology and Hematology,2009

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study;European Journal of Cancer Care;2019-04-10

2. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study;Future Oncology;2019-03

3. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study;Supportive Care in Cancer;2018-10-20

4. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis;European Journal of Haematology;2017-12-29

5. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz;Future Oncology;2017-10